None listed
Conditions
Brief summary
This study aims to test the feasibility of implementing and evaluating blood conservation strategies in blood cancer patients admitted to hospital. Who is it for? You may be eligible for this study if you are an adult inpatient with a haemotological malignancy commencing a chemotherapy protocol. Study details Participants will be randomly allocated to either receive blood conservation strategies (including smaller discard and blood collection volumes) when blood samples are obtained from their Central Venous Access Device (CVAD), or standard of care blood sampling protocols. Questionnaires assessing feasibility and clinical data regarding markers of anaemia will be collected. It is hoped that findings from this study will help determine the impact of hospital-acquired anaemia on patients’ anaemic status and symptoms and will lead to a larger, definitive trial of this.
Interventions
Intervention group: blood sampling frequency will occur as per standard of care. The following interventions will be implemented when blood is required for sampling:
- CVAD discard volume will be reduced from 10mL as per standard of care, to 4mL
- All blood samples taken, excluding blood cultures, will be in small volume blood tubes
- Documentation of all phlebotomy blood loss be recorded by nursing staff on patients’ fluid balance chart
Study interventions include:
- Small volume blood tubes (
Intervention group: blood sampling frequency will occur as per standard of care. The following interventions will be implemented when blood is required for sampling: - CVAD discard volume will be reduced from 10mL as per standard of care, to 4mL - All blood samples taken, excluding blood cultures, will be in small volume blood tubes - Documentation of all phlebotomy blood loss be recorded by nursing staff on patients’ fluid balance chart Study interventions include: - Small volume blood tubes (SST tube 3.5mL, EDTA tube 2mL, Citrate tube 3.5mL) - Decrease of CVAD discard volume to 4mL - Documentation of phlebotomy losses The duration of the intervention period is from enrolment until discharge or 28 days, whichever is less. Weekly checks will be performed by the study nurse for adherence via medical charts and observation.
Sponsors
Queensland University of Technology
Study design
Allocation
Randomised controlled trial
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
i. Inpatient on trial wards, and, ii. 18 years or older, and, iii. Commencing a chemotherapy protocol (induction or a bone marrow transplant protocol) via intravenous route for haematological malignancy or bone marrow transplant, and, iv. Any cycle of a patient’s treatment regime where a nadir, or low point of blood cell counts, is expected, and, v. CVAD insitu.
Exclusion criteria
i. Under 18 years of age. ii. Started chemotherapy protocol as an outpatient (e.g. consolidation protocol) and are admitted to hospital (e.g. neutropenic fevers). iii. Patients transferred from other clinical units (e.g. ICU, CCU) who have commenced chemotherapy protocol in that unit. iv. Patients receiving treatment for haematological malignancy in any other unit (e.g. CCU, ICU). v. Patients on an end-of-life pathway. vi. Cognitive barrier to consent. vii. Medicare ineligibility.
Outcome results
None listed